Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, Edupuganti VVSR, Hsu KS, Dower C, Yu G, So D, Bajgain P, Zhu Z, Dimitrov DS, Patel NL, Robinson CM, Difilippantonio S, Dyba M, Corbel A, Basuli F, Swenson RE, Kalen JD, Suthe SR, Hussain M, Italia JS, Souders CA, Gao L, Schnermann MJ, St Croix B.
Feng Y, et al. Among authors: dyba m.
Cell Rep. 2023 Dec 26;42(12):113503. doi: 10.1016/j.celrep.2023.113503. Epub 2023 Nov 28.
Cell Rep. 2023.
PMID: 38019654
Free PMC article.